Grants and Contracts Details
| Status | Active |
|---|---|
| Effective start/end date | 8/12/24 → 8/12/26 |
Funding
- PPD Development Inc: $18,740.00
24-HN-39-GSK (221530): A Randomized, Double-blind, Placebo-controlled Phase 3 Study to evaluate Dostarlimab as Sequential Therapy after Chemoradiation in Participants with Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
- Arnold, Susanne (PI)